At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Palbociclib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Palbociclib and Bazedoxifene for Breast Cancer Stage IV and 2 related conditions. Completed, enrolled 36 participants across 2 sites.
Detailed Summary
This research study is studying a drug called Palbociclib in combination with Bazedoxifene (a type of endocrine therapy, which prevents breast cancer cell growth by blocking estrogen stimulation) as a possible treatment for this diagnosis. The names of the study interventions involved in this study are: * Palbociclib * Bazedoxifene
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJul 2015
Primary CompletionAug 2019
Study CompletionMar 2021
TodayJul 2026
First PostedMay 19, 2015
Enrollment StartJul 9, 2015
Primary CompletionAug 12, 2019
Study CompletionMar 3, 2021
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 11.1 years ago
Interventions
Palbociclibdrug
Bazedoxifenedrug